Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 3/20 | 0.46 |
| ▸ | LDHB | P07195 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742440 | 0.88 | CYP3A4 (0.44) | AOC3 | |
| SCHEMBL1744351 | 0.87 | CHEK1 (0.46) | PIK3CGMAP4K4 | |
| SCHEMBL12159871 | 0.86 | AOC3 (0.38) | LDHALDHBAOC3CYP11B2SLC6A7 | |
| SCHEMBL1743223 | 0.82 | HRH3 (0.50) | LDHALDHBKMOAOC3 | |
| SCHEMBL1743030 | 0.82 | CYP11B2 (0.49) | CYP11B2 | |
| SCHEMBL1742838 | 0.79 | AKR1C3 (0.46) | LDHALDHBAXLAKR1C3AKR1C2 | |
| SCHEMBL1743183 | 0.78 | CLK4 (0.47) | CYP11B2 | |
| SCHEMBL1744142 | 0.76 | HTT (0.42) | — | |
| SCHEMBL1742352 | 0.72 | AOC3 (0.45) | AOC3SLC6A7 | |
| SCHEMBL1742848 | 0.72 | SMN1; SMN2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| CN-103110635-A | Histamine H3 receptor antagonist | NOVO NORDISK AS | 2013-05-22 | — | — | CN | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| CN-101218206-A | Histamine H3 receptor antagonists | NOVO NORDISK AS (DK) | 2008-07-09 | — | — | CN | disclosed |
| EP-1902028-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS | Novo Nordisk A/S (DK) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232078-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | LDHA 1338/4885LDHB 1176/4885PIK3CG 2476/4885 |
| US-20090312309-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | LDHA 1338/4885LDHB 1176/4885PIK3CG 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.